Bispecific Antibody Drug Conjugates for AML
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Acute Myelogenous Leukemia (AML) are hindered by the lack of specificity, leading to significant toxicity in healthy cells and limited efficacy due to the non-specific targeting of antigens, with existing therapies often causing off-target effects and relapse, particularly in CD7+ AML subtypes which are resistant to chemotherapy.
Innovation Solution
A dual targeting approach using cell inhibiting agents that bind to both CD33 and CD7, allowing for simultaneous targeting of AML cells, thereby inducing synergistic therapeutic effects and reducing off-target toxicity by exploiting the specific co-expression of these antigens on AML cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If single antigen targeting (CD33 or CD7) is used, then treatment simplicity is maintained, but therapeutic efficacy is insufficient and relapse occurs
Solution Approach 1:
The patent combines two separate single-antigen targeting therapies (anti-CD33 and anti-CD7) into a dual targeting combination. This merging approach leverages the synergistic effect of simultaneously engaging both CD33 and CD7 antigens on AML cells, resulting in enhanced therapeutic efficacy and reduced relapse rates compared to single-antigen targeting alone.
2Productivity
If conventional chemotherapy is used, then broad cancer cell killing is achieved, but significant toxicity occurs in healthy cells
Solution Approach 1:
The patent applies local quality by targeting specific antigens (CD33 and CD7) that are selectively expressed on AML cells rather than using non-specific chemotherapy agents. The anti-CD33 and anti-CD7 therapies deliver cytotoxic effects locally to cancer cells expressing these markers, spares healthy cells from widespread toxicity, and maintains high cancer cell killing efficiency through antigen-specific engagement.
3Ease of operation
If CD7+ AML subtypes are treated with standard chemotherapy, then treatment is administered, but resistance occurs and efficacy is limited
Solution Approach 1:
The patent addresses the dynamic nature of CD7+ AML subtypes by using a flexible combination approach that adapts to the specific antigen expression profile. The dual targeting strategy dynamically engages both CD33 and CD7 pathways simultaneously, overcoming the resistance mechanisms that limit standard chemotherapy efficacy in this resistant subtype while maintaining ease of administration through standardized protocol protocols.
Data Source
AI summary
This invention relates to the dual targeting of cell inhibiting agents to the cell surface receptors CD7 and CD33 in the treatment of hematological malignancy. In particular, the invention relates to cell inhibiting agents that bispecifically binds to CD33 and CD7 for use in the treatment of a CD7+CD33+ hematological malignancy. Such agents may comprise bispecific antibody drug conjugates.